Indication
Elago is a gonadotropin-releasing hormone (GnRH) receptor antagonist indicated
Dosage and Administration
Pregnancy should be excluded before starting Elago and bhstart Elago within 7 days from the onset of menses. Elago should be taken at approximately the same time each day, with or without food. Lowest effective dose, taking into account the severity of symptoms and treatment objectives. Initial treatment with Elago 200 mg twice daily up to 6 months (with coexisting dyspareunia). Treatment with Elago 200 mg should not exist more than 6 months as it may decrease bone mineral density (BMD) In case of moderate to severe hepatic impairment Elago 200 mg is not recommended.
Composition
Elago 200 mg Tablet: Each tablet contains 207.0 mg of elagolix sodium equivalent to 200 mg of elagolix INN.